AbbVie Rinvoq nabs EU approval in Crohn disease

AbbVie said Monday that the European Commission approved Rinvoq (upadacitinib) as the first oral JAK inhibitor for the treatment of adults with moderately-to-severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. The drug is also under review in the US in this indication. The European approval is supported by data from the two induction studies, U-EXCEED and U-EXCEL, along with the U-ENDURE maintenance trial. AbbVie noted that statistical significance was achieved for the co-primary endpoints and key secondary goals with Rinvoq 45mg in the induction studies and doses of 15mg and 30mg in the maintenance trial, compared to placebo. "The [EU] approval of Rinvoq in Crohn's disease is a significant milestone in offering patients the first and only once-daily oral treatment that can provide endoscopic improvement, and sustained symptom relief," remarked Thomas Hudson, AbbVie's chief scientific officer. Rinvoq's first authorisation in Crohn's disease came in February in the UK. Rinvoq is also authorised in the EU for the treatment of adults with radiographic axial spondyloarthritis, non-radiographic axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and for adults and adolescents with atopic dermatitis

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!